Function of Fibro-Adipogenic Progenitors in Heterotopic Ossification of Skeletal Muscle

纤维脂肪祖细胞在骨骼肌异位骨化中的功能

基本信息

  • 批准号:
    10218059
  • 负责人:
  • 金额:
    $ 33.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-08-01 至 2023-07-31
  • 项目状态:
    已结题

项目摘要

Project Summary Heterotopic ossification (HO), the formation of bone in skeletal muscle and associated soft tissues, can result from traumatic injury or disease. The most extreme form of HO is manifested in the rare, autosomal- dominant genetic disorder, Fibrodysplasia ossificans progressiva (FOP), in which HO continues progressively throughout life, resulting in devastating effects on health and life expectancy. We developed a new genetic model of FOP based on conditional expression of the disease-causing BMP receptor, Acvr1(R206H). Using this model, we identified fibro-adipogenic progenitors (FAPs), a multipotent mesenchymal progenitor in muscle tissue, as the disease-causing cell population. Notably, we have shown that intramuscular injection of BMP2 into wild type mice also leads to FAP-derived HO, suggesting mechanistic similarities of HO pathogenesis in FOP patients and the general population. Studies of HO have focused almost entirely on mechanisms of bone growth, yet severe muscle loss can be a significant contributing factor to patient morbidity. The overarching objectives of this research are to 1) understand how FAP programming becomes subverted for pathological bone formation; 2) understand how regeneration is inhibited in skeletal muscle susceptible to HO; 3) determine whether HO of skeletal muscle is entirely dependent on FAPs. By targeting Acvr1R206H expression to FAPs using PdgrfαCreER and Tie2-Cre drivers, Aim 1 will quantify regeneration impairment, and will determine whether muscle stem cell (satellite cell; SC) dysfunction is responsible for regeneration deficits. These studies will quantify SC proliferation and apoptosis after muscle injury and will define the SC mRNA transcriptome. Aim 1 will also determine whether Acvr1(R206H) expression in FAPs disrupts FAP-SC interactions. Aim 2 will use RNA-Seq to define the FAP transcriptome at early, critical, times after injury to identify gene targets of Acvr1(R206H) signaling. Gro-Seq (Genome-wide Run-On) analyses will quantify changes in active gene transcription, will identify candidate genes regulated by promoter-proximal polymerase pausing, and will identify potential enhancer targets of Acvr1(R206H) signaling. Lineage tracing will determine whether the abnormal muscle environment differentially affects the fate of normal and mutant FAPs. In Aim 3, DTA ablation approaches will determine whether FAPs are the sole source of osteogenic cells in muscle, information that is essential for evaluating the possible efficacy of cell-specific therapies. Activin inhibition has recently emerged as a powerful potential therapy for FOP. Aim 4 will use lineage tracing to address how Activin blockade affects proliferation, survival and developmental capacity of FAPs and SCs. RNA-Seq will define the extent to which Activin inhibition “normalizes” FAP and SC transcriptomes. The proposed research will contribute significantly to an understanding of the cells and cellular interactions responsible for HO and associated inhibition of muscle regeneration, and may lead to the development of strategies for cell-based therapies.
项目摘要 异位骨化(HO)是骨骼肌和相关软组织中骨的形成, 由外伤或疾病引起的。HO的最极端形式表现在罕见的常染色体- 显性遗传性疾病,进行性骨化性纤维发育不良(FOP),其中HO持续进行性 这对健康和预期寿命造成了毁灭性的影响。我们开发了一种新的基因模型 FOP基于致病BMP受体Acvr 1(R206 H)的条件表达。使用该模型, 我们鉴定了成纤维脂肪祖细胞(FAP),一种肌肉组织中的多能间充质祖细胞, 致病细胞群。值得注意的是,我们已经表明,肌肉注射BMP 2到野生型, 小鼠也导致FAP衍生的HO,表明FOP患者中HO发病机制的相似性, 一般人。HO的研究几乎完全集中在骨生长的机制上,但严重的 肌肉损失可能是患者发病率的重要影响因素。本组织的总体目标 研究是为了1)了解FAP编程如何被病理性骨形成破坏; 2) 了解如何在骨骼肌再生抑制HO敏感; 3)确定是否HO的 骨骼肌完全依赖于FAP。通过使用PdgrfαCreER将Acvr 1 R206 H表达靶向FAP 和Tie 2-Cre驱动程序,Aim 1将量化再生损伤,并将确定肌肉干细胞是否 (卫星细胞; SC)功能障碍是再生缺陷的原因。这些研究将量化SC增殖 和肌肉损伤后的细胞凋亡,并将定义SC mRNA转录组。目标1还将确定是否 FAP中的Acvr 1(R206 H)表达破坏FAP-SC相互作用。Aim 2将使用RNA-Seq来定义FAP 在损伤后的早期、关键时间,检测转录组,以鉴定Acvr 1(R206 H)信号传导的基因靶标。格罗塞克 (全基因组运行)分析将量化活性基因转录的变化, 调节启动子近端聚合酶暂停,并将确定潜在的增强子靶点, Acvr 1(R206 H)信号传导。谱系追踪将确定是否异常肌肉环境差异 影响正常和突变型FAP的命运。在目标3中,DTA消融方法将确定FAP是否 是肌肉中成骨细胞的唯一来源,这些信息对于评估可能的疗效至关重要 细胞特异性疗法激活素抑制最近已成为FOP的一种强大的潜在疗法。目标4 将使用谱系追踪来解决激活素阻断如何影响增殖,存活和发育能力 FAP和SC。RNA-Seq将定义激活素抑制使FAP和SC“正常化”的程度。 转录组拟议的研究将大大有助于了解细胞和细胞 负责HO的相互作用和相关的肌肉再生抑制,并可能导致 开发基于细胞的治疗策略。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification.
  • DOI:
    10.1002/jbmr.4617
  • 发表时间:
    2022-11
  • 期刊:
  • 影响因子:
    6.2
  • 作者:
    Yamamoto, Masakazu;Stoessel, Sean J.;Yamamoto, Shoko;Goldhamer, David J.
  • 通讯作者:
    Goldhamer, David J.
An anti-ACVR1 antibody exacerbates heterotopic ossification by fibro-adipogenic progenitors in fibrodysplasia ossificans progressiva mice.
  • DOI:
    10.1172/jci153795
  • 发表时间:
    2022-06-15
  • 期刊:
  • 影响因子:
    15.9
  • 作者:
    Lees-Shepard, John B.;Stoessel, Sean J.;Chandler, Julian T.;Bouchard, Keith;Bento, Patricia;Apuzzo, Lorraine N.;Devarakonda, Parvathi M.;Hunter, Jeffrey W.;Goldhamer, David J.
  • 通讯作者:
    Goldhamer, David J.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID J GOLDHAMER其他文献

DAVID J GOLDHAMER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID J GOLDHAMER', 18)}}的其他基金

Regulation of Satellite Cell Development, Programming and Differentiation by Myogenic Factors
成肌因子对卫星细胞发育、编程和分化的调节
  • 批准号:
    10451732
  • 财政年份:
    2020
  • 资助金额:
    $ 33.5万
  • 项目类别:
Regulation of Satellite Cell Development, Programming and Differentiation by Myogenic Factors
成肌因子对卫星细胞发育、编程和分化的调节
  • 批准号:
    10222571
  • 财政年份:
    2020
  • 资助金额:
    $ 33.5万
  • 项目类别:
Regulation of Satellite Cell Development, Programming and Differentiation by Myogenic Factors
成肌因子对卫星细胞发育、编程和分化的调节
  • 批准号:
    10670113
  • 财政年份:
    2020
  • 资助金额:
    $ 33.5万
  • 项目类别:
A new therapeutic approach for fibrodysplasia ossificans progressiva based on ACVR1 over-expression
基于ACVR1过表达的进行性骨化性纤维发育不良的新治疗方法
  • 批准号:
    9977124
  • 财政年份:
    2019
  • 资助金额:
    $ 33.5万
  • 项目类别:
Function of Fibro-Adipogenic Progenitors in Heterotopic Ossification of Skeletal Muscle
纤维脂肪祖细胞在骨骼肌异位骨化中的功能
  • 批准号:
    9975094
  • 财政年份:
    2017
  • 资助金额:
    $ 33.5万
  • 项目类别:
Function of Fibro-Adipogenic Progenitors in Heterotopic Ossification of Skeletal Muscle
纤维脂肪祖细胞在骨骼肌异位骨化中的功能
  • 批准号:
    9366782
  • 财政年份:
    2017
  • 资助金额:
    $ 33.5万
  • 项目类别:
FASEB Science Research Conference on Skeletal Muscle Satellite and Stem Cells
FASEB 骨骼肌卫星和干细胞科学研究会议
  • 批准号:
    8719376
  • 财政年份:
    2014
  • 资助金额:
    $ 33.5万
  • 项目类别:
The Cellular Basis of Heterotopic Ossification
异位骨化的细胞基础
  • 批准号:
    8269566
  • 财政年份:
    2010
  • 资助金额:
    $ 33.5万
  • 项目类别:
The Cellular Basis of Heterotopic Ossification
异位骨化的细胞基础
  • 批准号:
    8092623
  • 财政年份:
    2010
  • 资助金额:
    $ 33.5万
  • 项目类别:
The Cellular Basis of Heterotopic Ossification
异位骨化的细胞基础
  • 批准号:
    8460934
  • 财政年份:
    2010
  • 资助金额:
    $ 33.5万
  • 项目类别:

相似海外基金

心房細動に対するPulsed Field Ablationの組織創傷治癒過程を明らかにする網羅的研究
阐明房颤脉冲场消融组织伤口愈合过程的综合研究
  • 批准号:
    24K11201
  • 财政年份:
    2024
  • 资助金额:
    $ 33.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
  • 批准号:
    24K21101
  • 财政年份:
    2024
  • 资助金额:
    $ 33.5万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
遅延造影心臓MRIによる心房細動Ablation冷却効果の比較:28 vs. 31 mm Cryoballoon
使用延迟对比增强心脏 MRI 比较房颤消融冷却效果:28 毫米与 31 毫米 Cryoballoon
  • 批准号:
    24K11281
  • 财政年份:
    2024
  • 资助金额:
    $ 33.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CAREER: Heat Penetration Depth and Direction Control with Closed-Loop Device for Precision Ablation
职业:利用闭环装置控制热穿透深度和方向,实现精确烧蚀
  • 批准号:
    2338890
  • 财政年份:
    2024
  • 资助金额:
    $ 33.5万
  • 项目类别:
    Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
  • 批准号:
    2334777
  • 财政年份:
    2024
  • 资助金额:
    $ 33.5万
  • 项目类别:
    Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
  • 批准号:
    2334775
  • 财政年份:
    2024
  • 资助金额:
    $ 33.5万
  • 项目类别:
    Continuing Grant
InSPACE-VT_Development and Validation of Virtual Pace Mapping to Guide Catheter Ablation of Ventricular Tachycardia
InSPACE-VT_虚拟起搏测绘的开发和验证以指导室性心动过速导管消融
  • 批准号:
    EP/Z001145/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.5万
  • 项目类别:
    Fellowship
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
  • 批准号:
    2334776
  • 财政年份:
    2024
  • 资助金额:
    $ 33.5万
  • 项目类别:
    Continuing Grant
MRI: Acquisition of a Laser Ablation - Inductively Coupled Plasma - Triple Quadrupole - Mass Spectrometer (LA-ICP-QQQ-MS) System For Research and Education
MRI:获取用于研究和教育的激光烧蚀 - 电感耦合等离子体 - 三重四极杆 - 质谱仪 (LA-ICP-MS/MS) 系统
  • 批准号:
    2320040
  • 财政年份:
    2023
  • 资助金额:
    $ 33.5万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了